Assetmark Inc. Has $10.15 Million Stock Holdings in Boston Scientific Corporation $BSX

Assetmark Inc. decreased its position in Boston Scientific Corporation (NYSE:BSX) by 8.0% during the 4th quarter, according to the company in its most recent filing with the SEC. The fund owned 106,409 shares of the medical equipment provider’s stock after selling 9,204 shares during the quarter. Assetmark Inc.’s holdings in Boston Scientific were worth $10,146,000 at the end of the most recent reporting period.

Other large investors have also made changes to their positions in the company. Financial Consulate Inc. bought a new stake in shares of Boston Scientific in the 3rd quarter worth about $25,000. Murphy & Mullick Capital Management Corp boosted its stake in shares of Boston Scientific by 200.0% in the 3rd quarter. Murphy & Mullick Capital Management Corp now owns 255 shares of the medical equipment provider’s stock valued at $25,000 after purchasing an additional 170 shares during the last quarter. FWL Investment Management LLC bought a new position in shares of Boston Scientific in the 2nd quarter valued at about $26,000. United Community Bank raised its position in shares of Boston Scientific by 115.7% in the 3rd quarter. United Community Bank now owns 274 shares of the medical equipment provider’s stock valued at $27,000 after acquiring an additional 147 shares during the period. Finally, Colonial Trust Co SC raised its position in shares of Boston Scientific by 502.2% in the 3rd quarter. Colonial Trust Co SC now owns 277 shares of the medical equipment provider’s stock valued at $27,000 after acquiring an additional 231 shares during the period. Institutional investors own 89.07% of the company’s stock.

Insider Buying and Selling

In related news, CEO Michael F. Mahoney sold 160,901 shares of the company’s stock in a transaction that occurred on Monday, February 2nd. The stock was sold at an average price of $93.49, for a total value of $15,042,634.49. Following the sale, the chief executive officer directly owned 1,411,735 shares in the company, valued at $131,983,105.15. This represents a 10.23% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. 0.34% of the stock is owned by insiders.

Boston Scientific Stock Performance

NYSE:BSX opened at $64.28 on Friday. The stock has a market cap of $95.53 billion, a P/E ratio of 33.13, a price-to-earnings-growth ratio of 0.98 and a beta of 0.78. The company has a current ratio of 1.62, a quick ratio of 1.08 and a debt-to-equity ratio of 0.46. The stock’s 50-day moving average is $69.60 and its 200-day moving average is $86.96. Boston Scientific Corporation has a 1-year low of $60.59 and a 1-year high of $109.50.

Boston Scientific (NYSE:BSX) last announced its earnings results on Wednesday, February 4th. The medical equipment provider reported $0.80 EPS for the quarter, beating the consensus estimate of $0.78 by $0.02. Boston Scientific had a return on equity of 19.63% and a net margin of 14.44%.The business had revenue of $5.29 billion for the quarter, compared to analysts’ expectations of $5.29 billion. During the same period in the prior year, the business posted $0.70 earnings per share. The firm’s revenue was up 15.9% on a year-over-year basis. Boston Scientific has set its Q1 2026 guidance at 0.780-0.800 EPS and its FY 2026 guidance at 3.430-3.490 EPS. Equities research analysts anticipate that Boston Scientific Corporation will post 2.85 earnings per share for the current year.

Trending Headlines about Boston Scientific

Here are the key news stories impacting Boston Scientific this week:

• Positive Sentiment: Analysts are increasingly bullish, citing expectations for ~30% year‑over‑year growth in 2026 and constructive analyst commentary that supports upside to BSX’s earnings trajectory. Analysts Bullish on Boston Scientific (BSX)
• Positive Sentiment: Zacks previews point to robust cardiovascular momentum and steady MedSurg growth heading into Q1 results, implying potential upside to revenue and EPS vs. consensus if procedure trends hold. Will Robust Cardiovascular Performance Fuel BSX’s Q1 Earnings?
• Positive Sentiment: Boston Scientific is investing $88.4M to expand R&D operations in Ireland — a sign of continued product development and investment in innovation that supports medium‑term growth prospects. Boston Scientific invests $88.4M to expand R&D in Ireland
• Neutral Sentiment: Zacks also published a deeper Q1 preview on key operational metrics investors should watch (procedure volumes, segment mix, product cadence) that could swing reactions to the print beyond headline revenue/EPS. Boston Scientific (BSX) Q1 Earnings Preview
• Neutral Sentiment: Recent pieces revisiting BSX’s valuation and the impact of the Penumbra acquisition provide context on multiples and longer‑term returns; useful for investors framing position sizing but less likely to move intraday trading. A Look At Boston Scientific (BSX) Valuation
• Negative Sentiment: Multiple law firms have issued investor alerts and a class action has been filed alleging securities‑law violations for the July 23, 2025–Feb 3, 2026 period. These coordinated filings and lead‑plaintiff solicitations (with a May 4 deadline cited by several firms) are a near‑term headline risk that can pressure the stock or increase legal expenses/uncertainty. Representative notices and filings: PR Newswire: Shareholders Opportunity to Lead Securities Fraud Lawsuit Bronstein, Gewirtz & Grossman Class Action Notice Faruqi & Faruqi Deadline Reminder

Wall Street Analysts Forecast Growth

Several brokerages have commented on BSX. Weiss Ratings downgraded shares of Boston Scientific from a “buy (b-)” rating to a “hold (c+)” rating in a report on Wednesday, February 4th. Robert W. Baird reduced their price objective on shares of Boston Scientific from $118.00 to $101.00 and set an “outperform” rating for the company in a research report on Thursday, February 5th. Oppenheimer reduced their price objective on shares of Boston Scientific from $125.00 to $100.00 and set an “outperform” rating for the company in a research report on Friday, January 16th. National Bank Financial set a $115.00 price objective on shares of Boston Scientific in a research report on Monday, February 2nd. Finally, Wall Street Zen downgraded Boston Scientific from a “buy” rating to a “hold” rating in a report on Saturday, March 28th. One analyst has rated the stock with a Strong Buy rating, twenty-two have assigned a Buy rating and two have given a Hold rating to the company’s stock. According to MarketBeat, Boston Scientific has an average rating of “Moderate Buy” and a consensus target price of $102.82.

Boston Scientific Company Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.